p63: Molecular complexity in development and cancer.

Discovery of the p53 homologs p63 and p73 has brought new excitement to the p53 field. Identification of homologous genes coding for several proteins with similar and antagonistic properties towards p53 has been both intriguing and perplexing. A multitude of properties have been attributed to these new homologs and this review will focus on the biochemical and biological aspects of one family member, p63. Although the most ancient member of the p53 family, p63 is the most recently discovered and the least is known about this family member. Unlike p53, whose protein expression is not readily detectable in epithelial cells unless they are exposed to various stress conditions, p63 is expressed in select epithelial cells at high levels under normal conditions. p63 is highly expressed in embryonic ectoderm and in the nuclei of basal regenerative cells of many epithelial tissues in the adult including skin, breast myoepithelium, oral epithelium, prostate and urothelia. In contrast to the tumor suppressive function of p53, over-expression of select p63 splice variants is observed in many squamous carcinomas suggesting that p63 may act as an oncogene. Undoubtedly, the biochemical and biological activities attributed to p63 over the next several years will be diverse and regulation of the p63 gene and its several protein products complex. The use of various model systems and the study of human disease should continue to lead to rapid advances in our understanding of the role of p63 in development, epithelial cell maintenance and tumorigenesis.

[1]  E. Sturgis,et al.  Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. , 2002, Human pathology.

[2]  Xinbin Chen,et al.  p63α and ΔNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes , 2001, Oncogene.

[3]  J. Pietenpol,et al.  ΔNp63α Expression Is Regulated by the Phosphoinositide 3-Kinase Pathway* , 2003, Journal of Biological Chemistry.

[4]  Misako Sato,et al.  P63 expression in normal, hyperplastic and malignant breast tissues , 2002, Breast cancer.

[5]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[6]  C. Arrowsmith,et al.  Solution structure of a conserved C‐terminal domain of p73 with structural homology to the SAM domain , 1999, The EMBO journal.

[7]  D. Cerretti,et al.  Ligand Activation of ELK Receptor Tyrosine Kinase Promotes Its Association with Grb10 and Grb2 in Vascular Endothelial Cells* , 1996, The Journal of Biological Chemistry.

[8]  S. Nomoto,et al.  DeltaNp63 induces beta-catenin nuclear accumulation and signaling. , 2002, Cancer cell.

[9]  S. Chi,et al.  Frequent alteration of p63 expression in human primary bladder carcinomas. , 2000, Cancer research.

[10]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[11]  M. Augustin,et al.  Cloning and chromosomal mapping of the human p53-related KET gene to Chromosome 3q27 and its murine homolog Ket to mouse Chromosome 16 , 1998, Mammalian Genome.

[12]  E. Krieger,et al.  Gain-of-function mutation in ADULT syndrome reveals the presence of a second transactivation domain in p63. , 2002, Human molecular genetics.

[13]  G. Viale,et al.  p63, a p53 Homologue, Is a Selective Nuclear Marker of Myoepithelial Cells of the Human Breast , 2001, The American journal of surgical pathology.

[14]  E. Schröck,et al.  Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Cordon-Cardo,et al.  Loss of p63 expression is associated with tumor progression in bladder cancer. , 2002, The American journal of pathology.

[16]  K. Engeland,et al.  Differential regulation of transcription and induction of programmed cell death by human p53‐family members p63 and p73 , 2002, FEBS letters.

[17]  Ming-Rong Wang,et al.  Elevated expression of p63 protein in human esophageal squamous cell carcinomas , 2002, International journal of cancer.

[18]  J. Jen,et al.  Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma , 2000, International journal of cancer.

[19]  M. Kinch,et al.  E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[20]  D. Ponzin,et al.  p63 identifies keratinocyte stem cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Struhl,et al.  Nuclear Access and Action of Notch In Vivo , 1998, Cell.

[22]  D. Burstein,et al.  P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. , 2002, Human pathology.

[23]  T. Crook,et al.  High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? , 2000, Oncogene.

[24]  I. Leav,et al.  Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. , 2003, Human pathology.

[25]  A. Debant,et al.  The LAR transmembrane protein tyrosine phosphatase and a coiled‐coil LAR‐interacting protein co‐localize at focal adhesions. , 1995, The EMBO journal.

[26]  S. Granter,et al.  Adenoid basal carcinomas of the cervix: a unique morphological evolution with cell cycle correlates. , 2000, Human pathology.

[27]  Chikashi Ishioka,et al.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53 , 1998, Nature Medicine.

[28]  Ajay N. Jain,et al.  Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. , 2002, Cancer research.

[29]  B. Quade,et al.  Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. , 2001, Human pathology.

[30]  D. Bostwick,et al.  Adenoid Cystic/Basal Cell Carcinoma of the Prostate: Clinicopathologic Findings in 19 Cases , 2003, The American journal of surgical pathology.

[31]  A. Yang,et al.  A C-Terminal Inhibitory Domain Controls the Activity of p63 by an Intramolecular Mechanism , 2002, Molecular and Cellular Biology.

[32]  T. Pawson,et al.  PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Tabin,et al.  Molecular Models for Vertebrate Limb Development , 1997, Cell.

[34]  T. Tokino,et al.  Adenovirus‐mediated Transfer of p53‐related Genes Induces Apoptosis of Human Cancer Cells , 2000, Japanese journal of cancer research : Gann.

[35]  T. Rikiyama,et al.  p53 Homologue p63 Represses Epidermal Growth Factor Receptor Expression* , 2001, The Journal of Biological Chemistry.

[36]  S. Nomoto,et al.  ΔNp63 induces β-catenin nuclear accumulation and signaling , 2002 .

[37]  F. Bootz,et al.  Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck , 2002, International journal of cancer.

[38]  K. Münger,et al.  Oncoproteins encoded by the cancer-associated human papillomaviruses target the products of the retinoblastoma and p53 tumor suppressor genes. , 1991, Cold Spring Harbor symposia on quantitative biology.

[39]  Christopher P. Crum,et al.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development , 1999, Nature.

[40]  S. Zucoloto,et al.  The relationship between p63 and p53 expression in normal and neoplastic breast tissue. , 2009, Archives of pathology & laboratory medicine.

[41]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[42]  C. Bamberger,et al.  Retinoic Acid Inhibits Downregulation of ΔNp63α Expression During Terminal Differentiation of Human Primary Keratinocytes , 2002 .

[43]  M. Hild,et al.  Zebrafish DeltaNp63 is a direct target of Bmp signaling and encodes a transcriptional repressor blocking neural specification in the ventral ectoderm. , 2002, Developmental cell.

[44]  M. Mullins.  Embryonic axis formation in the zebrafish. , 1999, Methods in cell biology.

[45]  A. Aggarwal,et al.  RNA recognition via the SAM domain of Smaug. , 2003, Molecular cell.

[46]  B. Quade,et al.  Expression of the p53 homologue p63 in early cervical neoplasia. , 2001, Gynecologic oncology.

[47]  Wei Zhang,et al.  p63 expression profile in normal and malignant prostate epithelial cells. , 2002, Anticancer Research.

[48]  H. Ito,et al.  Mutation and transcription analyses of the p63 gene in cervical carcinoma. , 1999, International journal of oncology.

[49]  R. Mantovani,et al.  Complex Transcriptional Effects of p63 Isoforms: Identification of Novel Activation and Repression Domains† , 2002, Molecular and Cellular Biology.

[50]  M. Dai,et al.  SSRP1 functions as a co‐activator of the transcriptional activator p63 , 2002, The EMBO journal.

[51]  P. Beighton,et al.  Split-hand/split-foot malformation is caused by mutations in the p63 gene on 3q27. , 2000, American journal of human genetics.

[52]  Tzvi Aviv,et al.  The RNA-binding SAM domain of Smaug defines a new family of post-transcriptional regulators , 2003, Nature Structural Biology.

[53]  Elaine Fuchs,et al.  Getting under the skin of epidermal morphogenesis , 2002, Nature Reviews Genetics.

[54]  Raphael Kopan,et al.  Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain , 1998, Nature.

[55]  C. Cordon-Cardo,et al.  p63 expression profiles in human normal and tumor tissues. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  Peer Bork,et al.  SAM as a protein interaction domain involved in developmental regulation , 1997, Protein science : a publication of the Protein Society.

[57]  Marvin Miller,et al.  Hay‐Wells Syndrome , 1986, Pediatric dermatology.

[58]  J. Pietenpol,et al.  The ΔNp63α Phosphoprotein Binds the p21 and 14-3-3σ Promoters In Vivo and Has Transcriptional Repressor Activity That Is Reduced by Hay-Wells Syndrome-Derived Mutations , 2003, Molecular and Cellular Biology.

[59]  A. Lane,et al.  Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. , 1998, Genes & development.

[60]  B. Trink,et al.  p63α Mutations Lead to Aberrant Splicing of Keratinocyte Growth Factor Receptor in the Hay-Wells Syndrome* , 2003, Journal of Biological Chemistry.

[61]  K. Kihara,et al.  Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  R. Ladher,et al.  Signalling interactions during facial development , 1998, Mechanisms of Development.

[63]  H. Geddert,et al.  The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. , 2003, Human pathology.

[64]  A. Yang,et al.  Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. , 2000, Cancer research.

[65]  J. Reis-Filho,et al.  Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray , 2003, Virchows Archiv.

[66]  Michael Bamshad,et al.  Heterozygous Germline Mutations in the p53 Homolog p63 Are the Cause of EEC Syndrome , 1999, Cell.

[67]  M. Loda,et al.  Diagnostic Utility of Immunohistochemical Staining for p63, a Sensitive Marker of Prostatic Basal Cells , 2002, Modern Pathology.

[68]  B. Hogan.  Bone morphogenetic proteins in development. , 1996, Current opinion in genetics & development.

[69]  W. Gage,et al.  p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. , 2001, Urology.

[70]  A. Godzik,et al.  BAR: An apoptosis regulator at the intersection of caspases and Bcl-2 family proteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[71]  Yong Bae Kim,et al.  P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. , 2003, Gynecologic oncology.

[72]  James T. Elder,et al.  Cellular, immunologic and biochemical characterization of topical retinoic acid-treated human skin. , 1991, The Journal of investigative dermatology.

[73]  C. Tickle,et al.  Vertebrate limb development. , 1995, Current opinion in genetics & development.

[74]  M. Bamshad,et al.  p63 Gene mutations in eec syndrome, limb-mammary syndrome, and isolated split hand-split foot malformation suggest a genotype-phenotype correlation. , 2001, American journal of human genetics.

[75]  D. Kimelman,et al.  A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. , 2002, Developmental cell.

[76]  U. Pastorino,et al.  p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? , 2002, The Journal of pathology.

[77]  J U Bowie,et al.  p53 Family members p63 and p73 are SAM domain‐containing proteins , 1999, Protein science : a publication of the Protein Society.

[78]  D. Melton,et al.  Vertebrate Embryonic Cells Will Become Nerve Cells Unless Told Otherwise , 1997, Cell.

[79]  Michael C. Ostrowski,et al.  Ets-2 and Components of Mammalian SWI/SNF Form a Repressor Complex That Negatively Regulates the BRCA1Promoter* , 2003, The Journal of Biological Chemistry.

[80]  C. Bamberger,et al.  A novel protein with strong homology to the tumor suppressor p53 , 1997, Oncogene.

[81]  J. Jen,et al.  AIS is an oncogene amplified in squamous cell carcinoma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[82]  Y. Matsumura,et al.  TAp63γ (p51A) and dNp63α (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression , 2002, Oncogene.

[83]  T. Jacks,et al.  Sunburn and p53 in the onset of skin cancer , 1994, Nature.

[84]  Y. Samuels,et al.  ASPP1 and ASPP2: Common Activators of p53 Family Members , 2004, Molecular and Cellular Biology.

[85]  A. Fornace,et al.  Gadd45a regulates matrix metalloproteinases by suppressing ΔNp63α and β-catenin via p38 MAP kinase and APC complex activation , 2004, Oncogene.

[86]  F. McKeon,et al.  Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. , 1999, The Journal of investigative dermatology.

[87]  F. Schmitt,et al.  p63 expression in sarcomatoid/metaplastic carcinomas of the breast , 2003, Histopathology.

[88]  A. Mills,et al.  p63 is the molecular switch for initiation of an epithelial stratification program. , 2004, Genes & development.

[89]  Margaret Kasten,et al.  Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity , 2001, Oncogene.

[90]  K. Tsai,et al.  p63 and p73 are required for p53-dependent apoptosis in response to DNA damage , 2002, Nature.

[91]  Yu Shyr,et al.  Significance of p63 amplification and overexpression in lung cancer development and prognosis. , 2003, Cancer research.

[92]  H. Brunner,et al.  Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. , 2001, Human molecular genetics.

[93]  R. Sood,et al.  Modulation of TEL transcription activity by interaction with the ubiquitin-conjugating enzyme UBC9. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[94]  Michael Dohn,et al.  Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis , 2001, Oncogene.

[95]  J. Rhim,et al.  Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway , 2001, Nature Cell Biology.

[96]  X. Chen,et al.  The p53 family: same response, different signals? , 1999, Molecular medicine today.

[97]  J. Jen,et al.  A new human p53 homologue , 1998, Nature Medicine.

[98]  H. Vogel,et al.  p63 is a p53 homologue required for limb and epidermal morphogenesis , 1999, Nature.

[99]  Y. Barrandon,et al.  Three clonal types of keratinocyte with different capacities for multiplication. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[100]  K. Kihara,et al.  Impaired p 63 Expression Associates with Poor Prognosis and Uroplakin III Expression in Invasive Urothelial Carcinoma of the Bladder , 2003 .

[101]  C. Harris,et al.  Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. , 1999, Cancer research.

[102]  Yusuke Nakamura,et al.  The p53 Family Member Genes Are Involved in the Notch Signal Pathway* , 2002, The Journal of Biological Chemistry.

[103]  S. Hayward,et al.  Malignant transformation in a nontumorigenic human prostatic epithelial cell line. , 2001, Cancer research.

[104]  A. Bradley,et al.  p 63 is a p 53 homologue required for limband epidermalmorphogenesis , 2022 .

[105]  T. Jacks,et al.  p53 Family Members: p63 and p73 , 2005 .

[106]  P. Hall,et al.  Characterization of the expression pattern of p63α and δnp63α in benign and malignant oral epithelial lesions , 2000 .

[107]  T. Hunter,et al.  cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases , 1990, Molecular and cellular biology.